NCT06525974Not yet recruitingEarly phase 1
Clinical Study to Evaluate the Possible Efficacy and Safety of Febuxostat in Patients With Ulcerative Colitis Treated With Mesalamine
Source: ClinicalTrials.gov · Last updated 29 Jul 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Evaluation the possible efficacy and safety of febuxostat in patients with ulcerative colitis treated with mesalamine.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- First submitted
- 29 Jun 2024
- Start date
- 1 Sept 2024
- Primary completion date
- 30 Sept 2026
- Lead sponsor
- Tanta University
- Diseases
- Ulcerative colitis
- NCT number
- NCT06525974
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 46
- From 1 Sept 2024 to the primary completion date, 30 Sept 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients taking rectal or systemic steroids.
- Patients on immunosuppressants or biological therapies.
- Addiction to alcohol and / or drugs.
- Patients were treated with mercaptopurine.
Other illness
- Patients with Colorectal cancer patients.
- Known allergy to the studied medications.
- History of complete or partial colectomy.
- Patients with congestive heart failure, other heart disease (Arrhythmia, ischemic heart disease including angina and myocardial infarction).
- Patients with other inflammatory diseases and active infection.
- Patients with stressful condition (COPD, morbid obesity).
- Patients with liver disease.
Other
- Patients with severe UC.
- Significant liver and kidney function abnormalities.
- Diabetic patients.
- Patients with thrombocytopenia and neutropenia.
- Pregnant or lactating females.
Who the study is looking for
- Age ≥ 18 years old.
- Both male and female will be included.
- Mild and moderate UC patients diagnosed and confirmed by endoscope.
- Patient treated with 5-aminosalislic acid (mesalamine).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.